Plasminogen activator inhibitor type 1 gene polymorphism and thromboses in patients with antiphospholipid syndrome
- 作者: Reshetniak T1, Ostriakova E1, Patrusheva2 N2,3, Patrushev L4, Aleksandrova E1, Seredavkina N1, Volkov A1, Nasonov E1
-
隶属关系:
- ФГБУ "НИИ ревматологии" РАМН
- 1. ФГБУ "НИИ ревматологии" РАМН
- 2. ФГБУ "Институт биоорганической химии им. акад. М.М. Шемякина и Ю.А. Овчинникова" РАН, Москва
- ФГБУ "Институт биоорганической химии им. акад. М.М. Шемякина и Ю.А. Овчинникова" РАН, Москва
- 期: 卷 85, 编号 1 (2013)
- 页面: 76-84
- 栏目: Editorial
- URL: https://journals.rcsi.science/0040-3660/article/view/31214
- ID: 31214
如何引用文章
全文:
详细
作者简介
T Reshetniak
ФГБУ "НИИ ревматологии" РАМН
Email: t_reshetnyak@yahoo.com
11552 Москва, Каширское шоссе, 34а
E Ostriakova
ФГБУ "НИИ ревматологии" РАМН
Email: katerina.ostryakova@yandex.ru
N Patrusheva2
1. ФГБУ "НИИ ревматологии" РАМН; 2. ФГБУ "Институт биоорганической химии им. акад. М.М. Шемякина и Ю.А. Овчинникова" РАН, Москва
L Patrushev
ФГБУ "Институт биоорганической химии им. акад. М.М. Шемякина и Ю.А. Овчинникова" РАН, Москва
Email: tatayou@yandex.ru
E Aleksandrova
ФГБУ "НИИ ревматологии" РАМН
Email: aleksandrovaen@irramn.ru
N Seredavkina
ФГБУ "НИИ ревматологии" РАМН
Email: n_seredavkina@mail.ru
A Volkov
ФГБУ "НИИ ревматологии" РАМН
Email: sandyvlk@yahoo.com
E Nasonov
ФГБУ "НИИ ревматологии" РАМН
Email: socrat@irramn.ru
参考
- Насонов Е.Л. Антифосфолипидный синдром. М: Литтерра; 2004.
- Ruiz-Irastorza G., Crowther M., Branch W., Khamashta M.A. Antiphospholipid syndrome. Lancet 2010; 376: 1498-1509.
- Mehdi A.A., Uthman I., Khamashta M. Antiphospholipid syndrome: pathogenesis and a window of treatment opportunities in the future. Eur J Clin Invest 2010; 40: 451-464.
- Kornberg A., Blank M., Kaufman S., Shoenfeld Y. Induction of tissue factor-like activity in monocytes by anti-cardiolipin antibodies. J Immunol 1994; 153: 1328-1332.
- Amengual O., Atsumi T., Khamashta M.A., Hughes G.R. The role of the tissue factor pathway in the hypercoagulable state in patients with the antiphospholipid syndrome. Thromb Haemost 1998; 79: 276-281.
- Vega-Ostertag M., Casper K., Swerlick R. et al. Involvement of p38 MAPK in the up-regulation of tissue factor on endothelial cells by antiphospholipid antibodies. Arthritis Rheum 2005; 52: 1545-1554.
- Vega-Ostertag M., Harris E.N., Pierangeli S.S. Intracellular events in platelet activation induced by antiphospholipid antibodies in the presence of low doses of thrombin. Arthritis Rheum 2004; 50: 2911-2919.
- Alessi M.C., Juhan-Vague I. Contribution of PAI-1 in cardiovascular pathology. Arch Mol Ceur 2004; 97; 673-678.
- Tassies D., Espinosa G., Munoz-Rodriguez F. et al. The 4G/5G polymorphism of the type 1 plasminogen activator inhibitor gene and thrombosis in patients with antiphospholipid syndrome. Arthritis Rheum 2000; 43: 2349-2358.
- Forastiero R., Martinuzzo M., Adamczuk Y. et al. The combination of thrombophilic genotypes is associated with definite antiphospholipid syndrome. Haematologica 2001; 86: 735-741.
- Yasuda S., Tsutsumi A., Atsumi T. et al. Gene polymorphisms of tissue plasminogen activator and plasminogen activator inhibitor-1 in patients with antiphospholipid antibodies. J Rheumatol 2002; 29: 1192-1197.
- Asherson R.A., Khamashta M.A., Ordi-Ros J. et al. The "primary" antiphospholipid syndrome: major clinical and serological features medicine. Medicine (Baltimore) 1989; 68: 366-374.
- Myakis S., Lockshin M.D., Atsumi T. et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome. J Thromb Haemost 2006; 4: 295-306.
- Hochberg M.C. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1997; 40: 1725-1734.
- Brandt J.T., Triplett D.A., Alving B., Scharrer I. Criteria for the diagnosis of lupus anticoagulants: an update. On behalf of the Subcommittee on Lupus Anticoagulant / Antophospholipid Antibodies of the Scientific and Standardization Committee of the ISTH. Thromb Haemost 1995; 74: 1185-1190.
- Brandt J.T., Barna L.K., Triplett D.A. Laboratory identification of lupus anticoagulants: results of the Second International Workshop for identification of lupus anticoagulants. Thromb Haemost 1995; 74: 1597-1603.
- Баркаган З.С., Момот А.П. Диагностика и контролируемая терапия нарушений гемостаза. М: Ньюдиамед; 2001.
- Александрова Е.Н., Новиков А.А., Решетняк Т.М. и др. Диагностическое и прогностическое значение антител к кардиолипину, Β2-гликопротеину-1 и протромбину при антифосфолипидном синдроме. Клинико-лабораторный консилиум 2009; 2: 47-58.
- Eriksson P., Kallin B., van Hooft F.M. et al. Allele-specffic increase in basal transcription of the plasminogen-activator inhibitor 1 gene is associated with myocardial infarction. Proc Nat Acad Sci 1995; 92: 1851-1855.
- Roest M., van der Schouw Y.T., Banga J.D. et al. Plasminogen Activator Inhibitor 4G polymorphism is associated with decreased risk of cerebrovascular Mortality in Older Women. Circulation 2000; 101: 67-72.
- Wiklund P., Nilsson L., Nilsson S. et al. Plasminogen activator inhibitor-1 4G/5G polymorphism and risk of stroke: replicated findings in two nested case-control studies based on independent cohorts. Stroke 2005; 36: 1661-1665.
- Eddy A.A., Fogo A.B. Plasminogen activator inhibitor-1 in chronic kidney disease: evidence and mechanisms of action. J Am Soc Nephrol 2006; 17: 2999-3012.
- Liu R.M. Oxidative stress, plasminogen activator inhibitor 1, and lung fibrosis. Antioxid Redox Signal 2008; 10: 303-319.
- Loskutoff D.J. Structure of the human plasminogen activator inhibitor-1 gene: non-random distribution of introns. Biochemistry 1987; 26: 3763-3768.
- Nilsson I.M., Tengborn L. Impaired fibrinolysis: new evidence in relation to thrombosis. In: Jespersen J., Kluft C. and Korsgaard O. (eds). Clinical Aspects of Fibrinolysis and Thrombolysis. Esbjerg: South Jutland Univ Press 1983. 273-291.
- Francis R.B. Jr., Kawanishi D., Baruch T. et al. Impaired fibrinolysis in coronary artery disease. Am Heart J 1988; 115: 776-780.
- Schleef R.R., Higgins D.L., Pillemer E., Levitt L.J. Bleeding diathesis due to decreased functional activity of type 1 plasminogen activator inhibitor. Clin Invest 1989; 83: 1747-1752.
- Patrushev L. Fibrinolytic Disorders. In: F. Lang (eds). Encyclopedia of Molecular Mechanisms of Disease. Springer 2009: 657-659.
- Rallidis L.S., Megalou A.A., Papageorgakis N.H. et al. Plasminogen activator inhibitor 1 is elevated in the children of men with premature myocardial infarction. Thromb Haemost 1996; 76: 417-421.
- Van Goor M.L., García E.G., Leebeek F. et al. The plasminogen activator inhibitor (PAI-1) 4G/5G promoter polymorphism and PAI-1 levels in ischemic stroke. A case-control study. Thromb Haemost 2005; 93: 92-96.
- Margaglione M., Cappucci G., Colaizzo D., Giuliani N. The PAI-1 Gene Locus 4G/5G Polymorphism Is Associated With a Family History of Coronary Artery Disease. Arterioscler Thromb Vasc Biol 1998; 18: 152-156.
- Vaughan D.E., De Taeye B.M., Eren M. PAI-1 antagonists: predictable indications and unconventional applications. Curr Drug Targets 2007; 8: 962-970.
- Jorgenson E., Deitcher S.R., Cicek M. et al. Plasminogen activator inhibitor type-1 (PAI-1) polymorphism 4G/5G is associated with prostate cancer among men with a positive family history. Prostate 2007; 67: 172-177.
- Castelló R., España F., Vázquez C. et al. Plasminogen activator inhibitor-1 4G/5G polymorphism in breast cancer patients and its association with tissue PAI-1 levels and tumor severity. Thromb Res 2006; 117: 487-492.
- Hoffstedt J., Andersson I.L., Persson L. et al. The common -6754G/5G polymorphism in the plasminogen activator inhibitor-1 gene is strongly associated with obesity. Diabetologia 2002; 45: 584-587.
- Lundgren C.H., Brown S.L., Nordt T.K. et al. Elaboration of type-1 plasminogen activator inhibitor from adipocytes. A potential pathogenetic link between obesity and cardiovascular disease. Circulation 1996; 93: 106-110.
- Yamada N., Arinami T., Yamakawa-Kobayashi K. et al. The 4G/5G polymorphism of the plasminogen activator inhibitor-1 gene is associated with severe preeclampsia. J. Hum. Genet 2000; 45: 138-141.
- Fay W.P., Shapiro A.D., Shih J.L. et al. Brief report: complete deficiency of plasminogen-activator inhibitor type 1 due to a frame-shift mutation. New Eng J Med 1992; 327: 1729-1733.
- Решетняк Т.М., Фомичева О.А., Кондратьева Л.В. и др. Кардиоваскулярная патология и полиморфизм гена ингибитора активатора плазминогена 1 у больной системной красной волчанкой (описание случая). Тромбоз, гемостаз и реология 2011; 3: 29-35.
- Острякова Е.В., Патрушева Н.Л., Алексанкин А.П. и др. Гомозиготная мутация в гене ингибитора активатора плазминогена 1 у пациентов с антифосфолипидным синдромом. Описание случаев. Науч-практ ревматол 2011; 5: 83-89.
- Решетняк Т.М., Вавилова Т.В. Клинико-лабораторные критерии диагностики антифосфолипидного синдрома - что нужно знать практическому врачу (лекция). Клин лаб диагн 2010; 5: 12-22.